mosunetuzumab (bispecific antibody component)
E902883
CD20-directed CD3 T-cell engager
anticancer drug
biologic medicinal product
bispecific monoclonal antibody
therapeutic antibody
Mosunetuzumab is a bispecific monoclonal antibody that redirects T cells to attack CD20-expressing B cells, used in the treatment of certain B-cell malignancies.
Observed surface forms (1)
| Surface form | Occurrences |
|---|---|
| mosunetuzumab | 0 |
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf |
CD20-directed CD3 T-cell engager
ⓘ
anticancer drug ⓘ biologic medicinal product ⓘ bispecific monoclonal antibody ⓘ therapeutic antibody ⓘ |
| actsOnCellType |
B lymphocytes
ⓘ
T lymphocytes ⓘ |
| adverseEffect |
cytokine release syndrome
ⓘ
fatigue ⓘ headache ⓘ hypophosphatemia ⓘ infections ⓘ neutropenia ⓘ pyrexia ⓘ tumor flare ⓘ |
| belongsTo |
CD20-targeted therapies
ⓘ
T-cell redirecting therapies ⓘ |
| bindsTo |
CD20-expressing B cells
ⓘ
T cells via CD3 ⓘ |
| effectOnBCells | B-cell depletion ⓘ |
| effectOnImmuneSystem | T-cell activation ⓘ |
| hasAdministrationPattern | step-up dosing to mitigate cytokine release syndrome risk ⓘ |
| hasEffect | reduction of tumor burden in responsive B-cell malignancies ⓘ |
| hasMolecularType | humanized monoclonal antibody ⓘ |
| hasStructureFeature | bispecific binding domains for CD20 and CD3 ⓘ |
| hasTarget |
CD20
NERFINISHED
ⓘ
CD3 NERFINISHED ⓘ |
| immuneEffect |
forms immunologic synapse between T cells and B cells
ⓘ
promotes perforin and granzyme-mediated apoptosis of target B cells ⓘ |
| indication | treatment of certain B-cell malignancies ⓘ |
| isNot |
CAR T-cell therapy
ⓘ
chemotherapy ⓘ |
| isUsedAs | monotherapy in certain indications ⓘ |
| mechanismOfAction |
induces T cell–mediated cytotoxicity
ⓘ
redirects T cells to kill CD20-positive B cells ⓘ |
| pharmacologicalClass | bispecific T-cell engager antibody ⓘ |
| regulatoryStatus | approved for treatment of relapsed or refractory follicular lymphoma in adults ⓘ |
| requiresMonitoring |
complete blood counts
ⓘ
signs and symptoms of cytokine release syndrome ⓘ |
| routeOfAdministration |
intravenous infusion
ⓘ
subcutaneous injection ⓘ |
| targetExpressionRequirement | requires CD20 expression on malignant B cells ⓘ |
| therapeuticArea | hematologic oncology ⓘ |
| treats |
relapsed or refractory B-cell non-Hodgkin lymphoma
ⓘ
relapsed or refractory follicular lymphoma ⓘ |
| usedIn | adult patients ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.